Literature DB >> 29457700

Impact of home spirometry on medication adherence among adolescents with cystic fibrosis.

Aarti Shakkottai1, Niko Kaciroti2, Lauren Kasmikha1, Samya Z Nasr1.   

Abstract

OBJECTIVE: Medication adherence among adolescents with cystic fibrosis (CF) is often suboptimal and this has significant impact on their health and quality of life. The purpose of the study was to evaluate the impact of frequent home pulmonary function (PFT) monitoring on medication adherence among adolescents with CF. HYPOTHESIS: We hypothesized that weekly home PFT monitoring will improve adherence while not significantly adding to the treatment burden.
METHODS: Individuals aged 12-21 years with CF were provided a spirometer to measure PFTs weekly for 1 year. Results were reviewed weekly via telephone. PFT data were downloaded from the device during quarterly clinic visits. Adherence was calculated from prescription refill data and compared to the previous year. Perceptions of treatment burden were assessed using the CF questionnaire-revised (CFQ-R) quality of life measure. Health outcome measures including nutritional status and PFTs from clinic were collected for the study period and the year prior.
RESULTS: Thirty-nine subjects participated in the study. Mean age was 15.89 ± 2.18 years and 54% were female. Mean adherence to weekly spirometry monitoring was 59.47 ± 24.60%. Values generated on the device showed good correlation with those obtained in clinic. Mean medication possession ratio (MPR) was 60% in the previous year and 65% during the study (P = 0.04). Mean treatment burden scaled score on the CFQ-R was 68 at enrollment and 66 at study completion (P = 0.14).
CONCLUSIONS: Frequent home PFT monitoring is feasible in CF adolescents and could successfully improve medication adherence without significantly impacting treatment burden.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  adolescents; cystic fibrosis; home spirometry; medication adherence; medication possession ratios; prescription refill histories; pulmonary function tests

Mesh:

Year:  2018        PMID: 29457700     DOI: 10.1002/ppul.23950

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Patient generated health data use in clinical practice: A systematic review.

Authors:  George Demiris; Sarah J Iribarren; Katherine Sward; Solim Lee; Rumei Yang
Journal:  Nurs Outlook       Date:  2019-04-26       Impact factor: 3.250

2.  Health care costs related to home spirometry in the eICE randomized trial.

Authors:  Natalie Franz; Hannah Rapp; Ryan N Hansen; Laura S Gold; Christopher H Goss; Noah Lechtzin; Larry G Kessler
Journal:  J Cyst Fibros       Date:  2021-03-12       Impact factor: 5.482

Review 3.  Initiating home spirometry for children during the COVID-19 pandemic - A practical guide.

Authors:  C H Richardson; N J Orr; S L Ollosson; S J Irving; I M Balfour-Lynn; S B Carr
Journal:  Paediatr Respir Rev       Date:  2021-02-19       Impact factor: 5.526

4.  A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF.

Authors:  Stephanie Thee; Mirjam Stahl; Rainald Fischer; Sivagurunathan Sutharsan; Manfred Ballmann; Axel Müller; Daniel Lorenz; Dominika Urbanski-Rini; Franziska Püschner; Volker Eric Amelung; Carola Fuchs; Marcus Alexander Mall
Journal:  BMC Pulm Med       Date:  2021-04-21       Impact factor: 3.317

5.  Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic.

Authors:  George M Solomon; Julianna Bailey; James Lawlor; Peter Scalia; Gregory S Sawicki; Christopher Dowd; Kathryn A Sabadosa; Aricca Van Citters
Journal:  J Cyst Fibros       Date:  2021-12       Impact factor: 5.482

6.  Benefits of Telemonitoring of Pulmonary Function-3-Month Follow-Up of Home Electronic Spirometry in Patients with Duchenne Muscular Dystrophy.

Authors:  Eliza Wasilewska; Agnieszka Sobierajska-Rek; Sylwia Małgorzewicz; Mateusz Soliński; Ewa Jassem
Journal:  J Clin Med       Date:  2022-02-06       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.